Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C

Keyphrases

• Chronic Hepatitis C 100%
• Ropeginterferon alfa-2b 100%
• Pegylated Interferon alfa-2a 100%
• Adverse Events 35%
• Sustained Virological Response 35%
• Ribavirin 28%
• Clinical Analysis 28%
• Confidence Interval 21%
• Quality of Life 21%
• Randomized Clinical Trial 21%
• Relative Risk 21%
• Liver 21%
• All-cause Mortality 21%
• Pegylated Interferon 21%
• Risk of Bias 21%
• Patient-important Outcomes 21%
• High Risk 14%
• Treatment Discontinuation 14%
• Absence of Evidence 14%
• Serious Adverse Events 14%
• I(2) 14%
• Paucity 14%
• Blood Serum 14%
• Treatment History 7%
• Clinical Effect 7%
• Embase 7%
• Meta-analysis 7%
• Number of Patients 7%
• Cochrane Library 7%
• Hepatobiliary 7%
• Intention-to-treat Analysis 7%
• Intervention Effect 7%
• MEDLINE 7%
• Clinical Consequences 7%
• Subgroup Analysis 7%
• Genotype 3 7%
• Genotype 2 7%
• Cochrane Central Register of Controlled Trials 7%
• Safety Profile 7%
• Peginterferon 7%
• Surrogate Outcomes 7%
• Systematic Error 7%
• Random Effects Model 7%
• Cochrane 7%
• Random Error 7%
• Viral Treatment 7%
• Viral Genotype 7%
• Error Bias 7%
• Interval-based 7%
• Relative Risk Reduction 7%
• Genotype 1 7%
• Genotype 4 7%
• Patient-centered Outcomes 7%
• Fixed Effects 7%
• Science Citation Index Expanded 7%
• Chronic Hepatitis C Infection 7%
• Conference Abstracts 7%
• Abstract Journal 7%
• Standardized Data Collection 7%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Hepatitis C 100%
• Peginterferon Alpha2b 100%
• Peginterferon Alpha2a 100%
• Adverse Event 87%
• Alpha2a Interferon 87%
• Peginterferon Alpha 87%
• Randomized Clinical Trial 37%
• All Cause Mortality 37%
• Ribavirin 37%
• Peginterferon 37%
• Observational Study 12%
• Infection 12%
• Random Effects Model 12%
• Alpha2b Interferon Plus Ribavirin 12%